These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37700627)

  • 21. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
    Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
    Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
    Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
    Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
    Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
    Takahashi Y; Nomoto H; Yokoyama H; Takano Y; Nagai S; Tsuzuki A; Cho KY; Miya A; Kameda H; Takeuchi J; Taneda S; Kurihara Y; Atsumi T; Nakamura A; Miyoshi H;
    Diabetes Obes Metab; 2023 Jun; 25(6):1503-1511. PubMed ID: 36722623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
    Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
    Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
    Hoog M; Smith JL; Yu M; Peleshok J; Mody R; Grabner M
    Clin Ther; 2022 Jun; 44(6):873-887. PubMed ID: 35618571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
    Miyagawa J; Odawara M; Takamura T; Iwamoto N; Takita Y; Imaoka T
    Diabetes Obes Metab; 2015 Oct; 17(10):974-83. PubMed ID: 26179187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
    Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
    Metabolism; 2020 May; 106():154190. PubMed ID: 32109448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study.
    Singh P; Taufeeq M; Pesavento TE; Washburn K; Walsh D; Meng S
    Diabetes Obes Metab; 2020 May; 22(5):879-884. PubMed ID: 31943645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients.
    Morieri ML; Frison V; Rigato M; D'Ambrosio M; Tadiotto F; Paccagnella A; Simioni N; Lapolla A; Avogaro A; Fadini GP
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32301492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study.
    Brown RE; Abitbol A; Bajaj HS; Goldenberg R; Khandwala H; Abdel-Salam S; Aronson R
    Diabetes Res Clin Pract; 2019 Oct; 156():107820. PubMed ID: 31446111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
    Gerstein HC; Hart R; Colhoun HM; Diaz R; Lakshmanan M; Botros FT; Probstfield J; Riddle MC; Rydén L; Atisso CM; Dyal L; Hall S; Avezum A; Basile J; Conget I; Cushman WC; Hancu N; Hanefeld M; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Muñoz EGC; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):106-114. PubMed ID: 31924562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
    Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
    Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 40. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
    Boye KS; Sapin H; García-Pérez LE; Rosilio M; Orsini Federici M; Heitmann E; Jung H; Aigner U; Guerci B; Giorgino F; Norrbacka K
    Diabetes Ther; 2020 Oct; 11(10):2383-2399. PubMed ID: 32880876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.